3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
28
Phase 3
8
Phase 1
6
Phase 1/2
4
Phase 4
2
Phase 2/3
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
2
Prostate Cancer Metastatic
1
Interventions
Zoledronic Acid
14
Leuprolide
9
bicalutamide
6
Triptorelin Pamoate
6
Goserelin
6
luprolide acetate gel depot
5
enzalutamide
5
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
5
Dutasteride
5
fluciclovine F-18
3
darolutamide
3
Sodium Chloride
3
Prednisone
3
Magnetic Resonance Spectroscopy
3
Flutamide
3
Androgen Antagonists
3
Abiraterone Acetate
3
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
3
cabazitaxel
2
Propofol
2
Prednisolone
2
Lidocaine
2
Gonadotropin-Releasing Hormone
2
Finasteride
2
Dexamethasone
2
Desflurane
2
Ciprofloxacin
2
testosterone 17 beta-cypionate
1
semaglutide
1
polyethylene glycol 3350
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
Prostatic Neoplasms
×
cabazitaxel
×
Clear all
NCT02441894
2017-01-24
PEGAZUS
Sanofi
Phase 4
Completed
21 enrolled
NCT01649635
2016-07-06
PROSPECTA
Sanofi
Phase 4
Completed
45 enrolled